PMVP insider transaction filings
PMV Pharmaceuticals, Inc. — 40 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-05. Screen PMVP transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for PMVP between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — PMV Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-05 | 4 | FLOWERS KIRSTEN — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Stelzer Laurie — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | BAUM CHARLES M — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Gallagher Carol Giltner — Director | Grant/award (A): 42,000 (derivative) @ $0 · Gift (G): 42,000 (derivative) @ $0 · Gift (G): 42,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | LEVINE ARNOLD J — Director | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Carulli Michael — Chief Financial Officer | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Jalota Deepika — Chief Development Officer | Grant/award (A): 303,310 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Ticktin Robert — General Counsel & COO | Grant/award (A): 319,270 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Mack David Henry — President and CEO, Director | Grant/award (A): 744,960 (derivative) @ $0 | EDGAR |
| 2025-10-29 | 4 | Mack David Henry — President and CEO, Director | Option exercise (M): 220,643 @ $1.37 · Option exercise (M): 220,643 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP V LLC — 10% owner | Sale (S): 1,000,000 @ $1.52 | EDGAR |
| 2025-09-12 | 4 | ORBIMED ADVISORS LLC — 10% owner OrbiMed Capital GP V LLC — 10% owner | Sale (S): 500,000 @ $1.80 | EDGAR |
| 2025-07-03 | 4 | Jalota Deepika — Chief Development Officer | Sale (S): 33,065 @ $1.06 | EDGAR |
| 2025-07-03 | 4 | Carulli Michael — Chief Financial Officer | Sale (S): 28,249 @ $1.06 | EDGAR |
| 2025-07-03 | 4 | Ticktin Robert — General Counsel & COO | Sale (S): 23,151 @ $1.06 | EDGAR |
| 2025-07-03 | 4 | Mack David Henry — President and CEO, Director | Sale (S): 58,411 @ $1.06 | EDGAR |
| 2025-06-09 | 4 | FLOWERS KIRSTEN — Director | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Stelzer Laurie — Director | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Heyman Richard A. — Director | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | BAUM CHARLES M — Director | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Gallagher Carol Giltner — Director | Grant/award (A): 33,500 (derivative) @ $0 · Gift (G): 33,500 (derivative) @ $0 · Gift (G): 33,500 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | LEVINE ARNOLD J — Director | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Carulli Michael — Chief Financial Officer | Grant/award (A): 265,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Jalota Deepika — Chief Development Officer | Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-03-05 | 4 | Mack David Henry — President and CEO, Director | Grant/award (A): 800,000 (derivative) @ $0 | EDGAR |
| 2025-01-22 | 4 | Mack David Henry — President and CEO, Director | Option exercise (M): 91,750 @ $0.53 · Option exercise (M): 17,709 @ $0.53 · Option exercise (M): 91,750 (derivative) @ $0 · Option exercise (M): 17,709 (derivative) @ $0 | EDGAR |
| 2024-10-03 | 4 | Jalota Deepika — Chief Development Officer | Disposition to issuer (D): 22,674 (derivative) · Disposition to issuer (D): 68,100 (derivative) · Grant/award (A): 90,774 (derivative) · Disposition to issuer (D): 125,000 (derivative) · Grant/award (A): 125,000 (derivative) | EDGAR |
| 2024-10-03 | 4 | Carulli Michael — Chief Financial Officer | Disposition to issuer (D): 13,605 (derivative) · Disposition to issuer (D): 27,200 (derivative) · Grant/award (A): 40,805 (derivative) · Disposition to issuer (D): 75,000 (derivative) · Grant/award (A): 75,000 (derivative) | EDGAR |
| 2024-10-03 | 4 | Mack David Henry — President and CEO, Director | Disposition to issuer (D): 134,584 (derivative) · Disposition to issuer (D): 249,600 (derivative) · Grant/award (A): 384,184 (derivative) · Disposition to issuer (D): 330,000 (derivative) · Grant/award (A): 330,000 (derivative) | EDGAR |
| 2024-09-12 | 4 | Jalota Deepika — Chief Development Officer | Sale (S): 7,218 @ $1.50 | EDGAR |
| 2024-09-12 | 4 | Carulli Michael — Chief Financial Officer | Sale (S): 2,891 @ $1.50 | EDGAR |
| 2024-06-10 | 4 | FLOWERS KIRSTEN — Director | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Stelzer Laurie — Director | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Heyman Richard A. — Director | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | BAUM CHARLES M — Director | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Gallagher Carol Giltner — Director | Grant/award (A): 67,500 (derivative) @ $0 · Gift (G): 67,500 (derivative) @ $0 · Gift (G): 67,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | LEVINE ARNOLD J — Director | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | Jalota Deepika — Chief Development Officer | Grant/award (A): 95,555 @ $0 · Grant/award (A): 225,095 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | Carulli Michael — Chief Financial Officer | Grant/award (A): 82,220 @ $0 · Grant/award (A): 204,630 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | Mack David Henry — President and CEO, Director | Grant/award (A): 163,890 @ $0 · Grant/award (A): 519,915 (derivative) @ $0 | EDGAR |
Recent 8-K events — PMV Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-31 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-09 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=PMVP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →